Pacira Pharma (PCRX) Tops Q3 EPS by 20c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Pacira Pharmaceuticals, Inc. Reports Third Quarter 2015 Financial Results
October 27, 2015 7:30 AM EDT-- Total Revenues of $62.2 Million in Third Quarter --
-- EXPAREL® Net Revenues of $59.7 Million in Third Quarter --
-- Conference Call Today at 9 a.m. ET --
PARSIPPANY, N.J., Oct. 27, 2015 (GLOBE NEWSWIRE) --  Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today provided updates on EXPAREL® (bupivacaine liposome injectable suspension) for... More
